ERBB2 and glioblastoma: CAR T cells were shown to inhibit GL261/EGFRvIII tumor growth [155], and the potential of ErbB2-specific CAR-NK (NK-92/5.28) cells was demonstrated for adoptive immunotherapy of glioblastoma [100].